iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. engages in the development of biopharmaceutical therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immune-oncology therapeutics for patients, today announced that management will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023 at 1:30 p.m. ET.

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

iTeos Therapeutics, Inc. (ITOS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher

The mean of analysts' price targets for iTeos Therapeutics, Inc. (ITOS) points to a 304.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know

- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC  - Completed enrollment of monotherapy dose escalation arm in TIG-007 Phase 2 trial in multiple myeloma  - Completed enrollment of first dose cohort in Phase 1 trial of EOS-984  - Cash balance and investment balance of $644.9 million as of September 30, 2023 expected to provide runway through 2026 across a number of impactful portfolio milestones

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

iTeos Therapeutics is a clinical-stage biotech focused on developing immunotherapies for solid tumors, with a focus on non-small cell lung cancer (NSCLC). Their most advanced project is belrestotug, an antibody targeting the TIGIT immune checkpoint, being co-developed with GlaxoSmithKline. The company has a strong financial position with $216 million in cash and investments, providing them with the funds to see the fruits of their clinical trials.

iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail

iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?

iTeos Therapeutics focuses on developing immuno-oncology treatments for cancer patients, with a focus on TIGIT-targeted therapies. Roche's accidental disclosure of positive data on its anti-TIGIT therapy led to a surge in iTeos' stock value. iTeos has a strong financial position with $677.5M in liquid assets and a negative enterprise value, making it an attractive investment opportunity.

iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall

Roche Holding AG

Arcus Biosciences

Roche accidentally published positive interim results from a lung cancer treatment study, which boosted shares of rivals Iteos and Arcus.

How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%

Gilead Sciences

Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%, got a boost premarket on Wednesday after Roche AG RHHBY, -1.10% said there had been an “inadvertent disclosure” of interim data from a study of its anti-TIGIT therapy tiragolumab in non-small cell lung cancer. The interim results showed positive data for overall survival with tiragolumab, but the results were “not mature” at the time of the analysis that was disclosed, Roche said in a release.

Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination

iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates

Today, we circle back on small oncology concern iTeos Therapeutics, Inc. for the first time since last July. The company is advancing its two primary compounds in its pipeline and has a potentially lucrative partnership with GlaxoSmithKline. The stock also trades under the net cash on iTeos' balance sheet. An updated investment analysis follows in the paragraphs below.

iTeos Therapeutics: Trading Under Cash Value

ITeos Therapeutics, Inc. (ITOS) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to earnings of $1.82 per share a year ago.

ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates

–  Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens

iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates

Ichor Hlds

Vishay Intertechnology

Zymeworks Inc

FGI Industries Ltd

Himax Tech

Momo

Heading into unchartered territory in the market, investors may take comfort in acquiring the most undervalued stocks. Primarily, the less-popular enterprises offer the advantage of being exactly that: not hogging the spotlight.

The 7 Most Undervalued Stocks You Need to Know About

BuildABear

Hudson Technologies

Immersion

KVH Industries

Radiant Logistics

Silicom

While most financial advisors direct you toward established, large-capitalization companies because of their relatively safer business profile, small-cap stocks to buy may pack quite a punch for specific investors. For example, if you're young and have limited funds, smaller and therefore riskier enterprises may yield significant gains.

7 Small-Cap Stocks That Are Flying Under the Radar

Core Molding Technologies

TrueBlue

Vipshop Hlds

Enerplus

Kiniksa Pharmaceuticals Ltd

Perdoceo Education

While it's always nice to get a discount, with cheap stocks, it may be better to go for enterprises sitting in the sweet spot; that is, publicly traded securities that are cheap but not too cheap where investors might fret about possible value traps. On this list, I'm only going to target (as of the time of writing) equity shares that trade between $10 and $20.

7 Dirt-Cheap Stocks Sitting in the Sweet Spot

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates

- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant

iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Aptevo Therapeutics

Beam Therapeutics

Chimerix

Dynavax Technologies

Vir Biotechnology

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

The Top 7 Growth Stocks in Biotech

iTeos Therapeutics, Inc. has a major deal with GSK, but a rival drug failed, bringing iTeos Therapeutics down. This happened once before with another program.

iTeos Therapeutics: Able To Pull In Big Pharma Deals, Needs Follow-Through

WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the Cowen 43rd Annual Health Care Conference being held in Boston, MA on Tuesday, March 7, 2023 at 9:10 a.m. ET.

iTeos to Present at Cowen 43rd Annual Health Care Conference

Genfit - ADR

Harmony Biosciences Holdings

Regeneron Pharmaceuticals

Selecta Biosciences

Vertex Pharmaceuticals

While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.

The 7 Best Biotech Stocks to Buy for February 2023

WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference being held virtually on Tuesday, February 14, 2023 at 10:00 a.m. EST.

iTeos to Present at SVB Securities Global Biopharma Conference

AbCellera Biologics

BioNTech SE

Moderna

You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

- 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant

iTeos Provides Business Updates and Clinical Development Plans for 2023

News for iTeos Therapeutics, Inc. Stock (ITOS)